TwinBeech Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

TwinBeech Capital’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-88,530	Closed	-$2.03M	–	557
2025 Q2	$2.03M	Buy	88,530 +44,544	+101%	+$1.11M	0.05%	323
2025 Q1	$1.28M	Sell	43,986 -2,811	-6%	-$89.8K	0.02%	451
2024 Q4	$1.74M	Buy	+46,797	New	+$2.14M	0.03%	341
2024 Q3	–	Sell	-45,224	Closed	-$1.81M	–	663
2024 Q2	$1.81M	Sell	45,224 -71,845	-61%	-$2.98M	0.04%	342
2024 Q1	$5.14M	Buy	+117,069	New	+$6.05M	0.11%	208
2023 Q4	–	Sell	-13,992	Closed	-$643K	–	632
2023 Q3	$643K	Buy	+13,992	New	+$763K	0.01%	527
2023 Q1	–	Sell	-43,937	Closed	-$1.23M	–	593
2022 Q4	$1.23M	Buy	+43,937	New	+$1.28M	0.02%	498

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TwinBeech Capital's AMPH Position: Q3 2025 in Review

TwinBeech Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2025, closing a stake of 88,530 shares — an estimated $2.03M sold.

TwinBeech Capital first reported a position in AMPH in Q4 2022 and held it in 7 quarters. The position peaked at $5.14M in Q1 2024. 243 funds tracked by Wall St. Rank hold AMPH as of Q3 2025.

TwinBeech Capital reported no remaining Amphastar Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 88,530 Amphastar Pharmaceuticals shares in Q3 2025, an estimated $2.03M.
TwinBeech Capital first reported a position in Amphastar Pharmaceuticals in Q4 2022 and held it in 7 quarters.
TwinBeech Capital's Amphastar Pharmaceuticals position peaked at $5.14M in Q1 2024.
243 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.